title: In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species.
abstract: In vitro interactions of INK128, a target of rapamycin (TOR) kinase inhibitor, and antifungals, including itraconazole, voriconazole, posaconazole, amphotericin B, and caspofungin, against Aspergillus spp. were assessed with the broth microdilution checkerboard technique. Our results suggested synergistic effects between INK128 and all azoles tested, against multiple Aspergillus fumigatus and Aspergillus flavus isolates. However, no synergistic effects were observed when INK128 was combined with amphotericin B or caspofungin. No antagonism was observed for any combination.
authors.affiliation: Department of Dermatology, Zhongshan Hospital Fudan University, Shanghai, People's Republic of China gao_lujuan@163.com jzzxyysy@163.com.
authors.forename: Lujuan
authors.initials: L
authors.lastname: Gao
authors.affiliation: Department of Dermatology, Jingzhou Central Hospital, Jingzhou City, Hubei Province, People's Republic of China.
authors.forename: Xiaozhen
authors.initials: X
authors.lastname: Ding
authors.affiliation: Yangtze University, Jingzhou City, Hubei Province, People's Republic of China.
authors.forename: Zhun
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Dermatology, Jingzhou Central Hospital, Jingzhou City, Hubei Province, People's Republic of China.
authors.forename: Qingzhi
authors.initials: Q
authors.lastname: Wu
authors.affiliation: Department of Dermatology, Jingzhou Central Hospital, Jingzhou City, Hubei Province, People's Republic of China.
authors.forename: Tongxiang
authors.initials: T
authors.lastname: Zeng
authors.affiliation: Department of Dermatology, Jingzhou Central Hospital, Jingzhou City, Hubei Province, People's Republic of China gao_lujuan@163.com jzzxyysy@163.com.
authors.forename: Yi
authors.initials: Y
authors.lastname: Sun
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D001231:Aspergillus flavus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000378:metabolism; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000378:metabolism; D001583:Benzoxazoles / Q000494:pharmacology*; D000077336:Caspofungin; D004338:Drug Combinations; D004357:Drug Synergism; D054714:Echinocandins / Q000494:pharmacology; D005656:Fungal Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D017964:Itraconazole / Q000494:pharmacology*; D055666:Lipopeptides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D011743:Pyrimidines / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole / Q000494:pharmacology*; D000225:Adenine / Q000031:analogs & derivatives
chemical_list: D000666:Amphotericin B; D000935:Antifungal Agents; D001583:Benzoxazoles; D000077336:Caspofungin; D004338:Drug Combinations; D054714:Echinocandins; D005656:Fungal Proteins; D017964:Itraconazole; D055666:Lipopeptides; D011743:Pyrimidines; D058570:TOR Serine-Threonine Kinases; D014230:Triazoles; D065819:Voriconazole; C101425:posaconazole; C572449:sapanisertib; D000225:Adenine